日本語 >>
TOP page
Journal
Presentation
（Last updated : 2022-06-03 11:12:43）
谷岡 洋亮
Department
,
Position
Assistant Professor with Special Assignment
■
Journal
1.
2022/05
Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study
2.
2022/05
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
3.
2021/11
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
4.
2021/05/12
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
5.
2021/05
Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations
6.
2021/03/17
Safety and e cacy of panitumumab in combination with tri uridine/ tipiracil for pre‐treated patients with unresectable, metastatic colorectal cancer with wild‐type RAS: The phase 1/2 APOLLON study
7.
2021/02
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
8.
2020/11/21
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
9.
2020/08/31
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
10.
2020/08/24
Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study
11.
2020/07/21
Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary
12.
2020/04/18
Prognostic nutritional index as a predictor of postoperative outcome in patients aged 85 years or older after colorectal cancer surgery
13.
2020/03/24
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
14.
2020/02/03
Upregulation of microRNA‐31 is associated with poor prognosis in patients with advanced colorectal cancer
15.
2020/01/21
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
16.
2019/12
A Case of Long-Term Survival after Para-Aortic Lymph Node Recurrence Following the Curative Resection of Gastric Cancer Treated Using Multimodality Therapy Including Salvage Surgery.
17.
2019/10/11
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
18.
2019/05
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
19.
2019/02
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the e cacy and safety
20.
2018/10
Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer
21.
2018/09
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial
22.
2018/08
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer
23.
2018/07
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical bene t in response to prior cetuximab: A retrospective study
24.
2018/03
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Display 5 items
Display all(24)
■
Presentation
1.
2022/03/04
REVIVE試験：ニボルマブの奏効別の救済化学療法の治療効果について
2.
2022/02/17
A Phase III trial of sequential versus combination in metastatic colorectal cancer: C-Cubed study
3.
2022/02/17
Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy
4.
2022/02/17
REVIVE study: An Observational Study in Chemotherapy (CTx) after Nivolumab (NIVO) for Advanced Gastric Cancer (AGC)
5.
2022/01/21
A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
6.
2022/01/21
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC)
7.
2021/11/12
Validation and development of the diagnostic technology for Lynch syndrome exclusion by a DNA
chip detecting MLH1 methylation and BRAF V600E mutations in colorectal cancer
8.
2020/01/23
A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI).
9.
2020/01/23
Multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII).
10.
2019/09/29
Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
11.
2019/09/29
Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
12.
2019/07/18
Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer
13.
2019/07/18
Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06
14.
2019/07/05
Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors
15.
2019/07/04
Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol
16.
2019/06/03
Validation of biomarkers of preoperative chemoradiotherapy for advanced low rectal cancer and extraction of the high-risk group of recurrence
17.
2019/04/01
Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells
18.
2019/01/19
Analysis of UGT1A's polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer.
19.
2019/01/19
CEA response at four weeks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab-based chemotherapy: A STEP-analysis in the JACCRO CC-05/06 trials.
20.
2019/01/19
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
21.
2018/11/24
Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer.
22.
2018/11/24
Incidence of catheter-related thrombosis in patients with long-term indwelling central venous catheter who received chemotherapies for unresectable advanced digestive cancers
23.
2018/11/10
Clinico-pathological features of hypermutant colorectal cancers analyzed over 1000 colorectal cancer
24.
2018/10/22
Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors
25.
2018/10/21
Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients
26.
2018/06/20
A phase I/II study of panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: APOLLON study
27.
2018/06/04
Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.
28.
2018/06/03
A randomized phase II study of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
29.
2018/06/03
APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).
30.
2018/06/03
Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel+/-trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).
31.
2018/03/08
A phase II study of S-1 and oxaliplatin for HER2-negative advanced gastric cancer (KSCC1501A)
Display 5 items
Display all(31)
